- Email: [email protected]
Index to volume 27 subject index
CONTRACEPTION
INDEX TO VOLUME 27 SUBJECT INDEX
A-LH-RH (IN-A~-D-T~$~~ ,D-p-Cl-Phe2D-Phe6,D-Ala101 Abortifacient
effect,
synthetic
androstane
derivatives
-LH-RP) (baboon), 201
Acceptability, comparison
of ethinyl oestradiol
triphasic norethisterone Accidental
versions,
+ levonoreestrel
during breast-feeding,
pregnancy,
monophasic
and
439
randomised
563
comparative
evaluation
of Cu-IIJDs, 75
1B-Acetoxy-l7a-ethinyl-l7-hydroxy-l8-methyl-4-ostren-3-on,
abortifacient
effect
(baboon), 201 16-178-Acetoxy-18-methyl-4-ostren-3-on, Age, effect Agonistic
on incidence
abortifacient
of pelvic inflammatory
analogue of LH-RH, D-Trp’-LH-RH,
Aldosterone
effect
disease during Cu-7 clinical
trials, ill
619
level,
effect
of ethinylestradiol
+ desogestrel
monophasic,
effect
of ethinylestradiol
+ desogestrel
sequential,
effect
of ethinylestradiol
+ levonoreestrel
AndrogenWantiandrogenic Androstane
(baboon), 201
derivatives,
5-Androstene-3,
activity,
l’l-dione, effect
Anemia development
effect
abortifacient
577 577
triphasic,
577
of RMI 12,936 (rat), 95
effect
(baboon), 201
on 178-hydroxysteroid
after T Cu 220 insertion,
predictive
oxidoreductase
activity
(dog), 431
value of serum ferritin,
289
Anemic women, effects
of ethynylestradiol
+ levonorpestrel
iron and iron binding capacity, effects
of ethynylestradiol of hemoglobin,
effects
on levels of hemoglobin,
serum
311
+ levonorgestrel
with ferrous
fumarate
serum iron and iron binding capacity,
of IUDs on levels of hemoglobin,
on levels
311
serum iron and iron binding capacity,
Anovulatory
luteal cycles (monkey), 505
Antagonistic
activity,
Antagonistic
analogue of LH-RH, [N-Ac-D-Trp1y3 ,D-p-C1-Phe2,D-Phe6,D-Ala101
deglycosylated
311
hCG (rat), 515 -
LH-RH, 619 Anti-hCG
antiserum,
antibody
titers
using the recommended
binding of hormones
and subunits,
JUNE 1983VOL. 27 NO. 6
standard
assay, 627
627
651
CONTRACEPTION characterization,
6’27
determination Antifertility
of isoantibody
Antigonadotropic
activity,
Antirwogestetional
effect
steroid,
Asialo hCG, effect
RMI 12,936, 95 activity,
effect
of RMI 12,936 (rat), 95
on action of hCG (rat), 515
bCH (baboon chorionic effect
Bile lithogenic
95
of RMI 12,936 (rat), 95
Antiuterotrophic/antiestroPedic
bCH level,
class, 627
assay, RMI 12,936 (hamster),
gonadotropin)
of synthetic
androstane
derivative
(baboon), 201
index,
effect
of ethinyl estradiol
effect
of norethisterone
+ I-norgestrel, enanthate,
591
591
Biliary lipid composition, effect
of ethinyl estradiol
effect
of norethisterone
Biological
activity
Biological
observations,
Biological
properties,
+ I-norqestrel, enanthate,
of Wtrp’-pro’
Bleeding duration, Bleeding patterns,
aaueous crude extract
versions,
effect
assessment
for stability
of solutions,
195
211 (guinea pip), 239
of ethinyl oestradiol + levonorgestrel
comparison
triphasic
591
-NEt-LHRH,
zoapatle, zoaoatle
591
monophasic
and
439
of norethisterone
during breast-feeding,
563
Blood chemistry, effect
of testosterone
effect
of zoapatle
Blood clotting,
effect
+ estradiol
implant (monkey), 363, 383
aqueous crude extract
of testosterone
(rat), 255
+ estradiol
implant (monkey\,
363
Blood loss at vacuum aspiration, comparison
of different
cervical pre-operative
prostaglandin
dilatation
analowes
in late first trimester
16,16-dimethyl-trans-
and laminaria abortion,
A~PGE~ methyl ester,
for preoperative
51 339
Blood pressure, comparison
of mestranol + norethindrone
effect
of levonorgestrel-releasing
effect
of Nova-T, 473
Blood production
rate of estradiol,
Blood production
rate of testosterone,
and ethipyl estradiol + norethindrone,
capsules,
effect
of testosterone
effect
453
473 + estradiol
of testosterone
implant (monkey) 347
+ estradiol
implant
(monkey), 347
652
JUNE 1983 VOL. 27 NO. 6
CONTRACEPTION Body weight, of mestranol + norethindrane
comparison effect
of levonorgestrel-releasing
effect
of lithosperm
(chick), 639
effect
of lithosperm
and propylthiouracil
effect
of Nova-T, 473
effect
of zoapatle
Botanical
and ecological
and ethinql estradiol
capsules,
453
473
(chick), 639
aoueous crude extract determinants,
+ norethirdrone,
(rat, dog:), 255
zoapatle,
227
Breast-feeding, acceptability effect
of norethisterone,
of oral contraceptive
Breast-feeding
duration,
Cadmium-induced
sterility,
Capsules containing
effect
of zirc (rat), 521
plasma levels during continuous levonorgestrel,
Caude epididymides,
effect
dilatation
contraception
administration,
123
enalogues
in termination
abortion,
and laminaria,
Cervical
dilatation
Cervical
mucus changes,
of first trimester
Cervical
state at time of vacuum aspiration,
A 2 PGEl methyl ester, enovulatory
A ’ PGEl methyl ester, Characterization
after pregnancy
termination,
473
of gossypol (rat), 391
in late first trimester
prosteglandin
Cholesterol
563
rate, 483
Capsules releasing Cervical
531
of norethisterone,
levonorgestrel,
levonorgestrel release
effect
563 regimens,
comparison
of different
51 pregnancy,
16,16-dimethyl-trens-
339 luteal cycle (monkey), 505 pre-operative
16,16-dimethyl-trens-
339
of e human anti-hCG
antiserum,
627
level,
effect
of injectable
medroxyprogesterone
effect
of subdermal
implant capsules
effect
of TCu 200, 281
Chrometogrephic
acetate,
containing
profile of D-trp’-pro’-NEt-LHPH,
161 levonorpestrel,
assessment
281
for stability
of solutions,
195 Clinical chemistry
tests,
effect
of subdermal
implant capsules
effect
of TCu 200, 281
containing
levonorgestrel,
281
Clinical date, first trimester delivery
JUNE
pregnancy
termination
system containing
1983 VOL. 27 NO. 6
using polymeric
controlled
release
vaginal
(15S)15-methyl PGF20 methyl ester, 141
653
CONTRACEPTION second trimester
pregnancy
vaginal delivery Clinical factors
influencing
Clinical observations, Clinical studies, Clotting
pill efficacy,
zoapatle,
zoapatle
termination
using polymeric
system containing
controlled
(15S)15-methyl PGF2u
release
methyl ester,
141
531
‘211
aoueous crude extract
(rat, dog), 255
activity, interaction
between
ethanol and ethinyl estradiol
interaction
between
ethanol and norethindrone
Comparative
evaluation
Complications
of copper 7, Multiload copper 250 and T copper-220C
after discharge methyl ester,
Compounds
isolated
(rat), 401
(rat), 401
from hospital,
pre-operative
IUPs, 75
16,16-dimethyl-trans-A
‘PGEl
339
from zoapatle,
211
Continuation, levonorgestrel-releasing
capsules,
473
Nova-T, 473 Continuation/withdrawal, and triphasic Continuation
versions,
of mestranol
of vitamin supplementation efficacy,
testosterone
Contraceptive
methods,
prevalence
Contragestative
effects,
Copper corrosion, Copper T, fertility Corrosion Cortisol
Cortisol
and ethinyl estradiol
during oral contraceptive
+ estradiol
453
use, 465
implant (monkey), 383
rate of vaginal colonization
RMI 12,936 (hamster),
+ norethindrone,
of -E. __ coli, 497
95
MLCu250 and MLCu375 IUDs, 85 regulation
in nursing women, 13
and time of use, MLCu250 and MLCu375 IUDs, 85 of fiIamentous
intrauterine
copper, MLCu250 and MLCu375, 85
binding globulin level, effect
of ethinplestradiol
+ desopestrel
monophasic,
effect
of ethinylestradiol
+ desogestrel
seouential,
effect
of ethinylestradiol
+ levonorgestrel
effect
of ethinylestradiol
+ desogestrel
effect
of ethinylestradiol + desogestrel
effect
of ethinylestradiol
effect
of subdermal
effect
of TCu 200, 281
577 577
triphasic,
577
monophasic,
577
level,
Covered rods containing
654
439
+ norethindrone
Contraceptive
Corrosion
monophasic
rate,
comparison effect
of ethinyl oestradiol + levonorgestrel
comparison
+ levonorgestrel
sequential,
577
triphasic,
implant capsules containing
577
levonorgestrel,
28 1
levonorgestrel,
JUNE
1983 VOL. 27 NO. 6
CONTRACEPTION levonorgestrel release
plasma levels during continuous
administration,
123
rate, 483
cu-7, incidence
of pelvic inflammatory
randomised
comparative
disease in clinical trials,
evaluation
111
of Cu-IUDs, 75
Cycle length, anovulatory
luteal cycle (monkey), 505
comparison
of ethinyl oestradiol
versions, effect
of agonistic
D-Trp’-LH-RH,
effect
and antagonistic
on ovulation
D-trp’-pro’-NEt-LHRH,
hCG, effect
of stability
on ovulation
of prolactinomas,
20 c1-Dihydroprogesterone
influence
preoperative
in
steroids,
69
progesterone
phase, 177
abortion,
comparison
of first trimester
pregnancy,
of different
prostaglandin
16,16-dimethyl-
339
’ PGEl methyl ester, cervical
dilatation
cervical
Duration of use, effect
effect
regimens,
51
of first trimester
pregnancy,
339
563
531
of norethisterone,
on incidence
clinical trials,
in termination
during breast-feeding,
oral contraceptive
Duration of breast-feeding,
in late first trimester,
dilatation
norethisterone
Drug interactions,
dilatation
51
A2 PGEl methyl ester,
pre-operative Discontinuation,
cervical
of vaginal device releasing
and laminaria,
of cervix in termination
16,16-Dimethyl-trans-A
39
of oral contraceptive
of cervix in late first trimester
trans-
195
(rat), 515
during proliferative
analogues
of solutions, contraception,
51
level, effect
prematurely
Dilatation
and triphasic
of LH-RH (monkey), 619
PGE2, preoperative
late first trimester,
Dilatation
analogues
when used for postcoital
9-Deoxo-16,16-dimethyl-9-methylene Development
monophasic
(monkey), 619
assessment
Danazol, side effects Deglycosylated
+ levonorgestrel
439
563
of pelvic inflammatory
disease during Cu-7
111
Dysmenorrhea, effect
of levonorgestrel-releasing
effect
of Nova-T, 473
capsules,
473
E. coli vaginal colonization, significantly associated factors, 497 -Early first trimester pregnancy termination, polymeric controlled release delivery
JUNE
system containing
1983 VOL. 27 NO. 6
(15S)15-methyl
vaginal
PGF2 o methyl ester,
141
655
CONTRACEPTION Ecological and botanical determinants, zoapatle, 227 Effectiveness Efficacy,
and interfering factors, oral contraceptive regimens, 531
comparison of ethinyl oestradiol + levonorgestrel monophasic and triphasic versions, 439
Ejaculate volume, effect of testosterone + estradiol implant (monkey), 363 Electric pump, use in vacuum aspiration, 63 Endocrine properties, effect of RMI 12,936 (rat, hamster, rabbit), 95 Endometrial effect,
progesterone released prematurely during proliferative phase, 177
Endometrial plasminogen activator activity, effect of IUDs, 131 Endometrium, subcellular distribution of estradiol and estrone during menstrual cycle, 409 Epididymis, effect of gossypol (rat), 391 Estradiol + testosterone, contraceptive
efficacy
(monkey), 383
effect on testis function (monkey), 347 somatic tissue responses (monkey), 363 Estradiol and estrone, subcellular distribution in endometrium and myometrium during menstrual cycle, 409 Estradiol blood production rate, effect of testosterone + estradiol implant (monkey), 347 Estradiol level, during menstrual cycle, 409 during menstrual cycle of lactating women, 299 effect of A-LH-RH (monkey), 619 effect of D-Trp’-LH-RH
(monkey), 619
effect of ethinylestradiol + desogestrel monophasic, 577 effect of ethinylestrediol + desogestrel sequential, 577 effect of ethinylestradiol + levonorgestrel triphasic, 577 effect of ethinyl estradiol + norgestrel during menstrual cycle of lactating women, 299 effect of norethisterone enanthate, 553 effect of Nova-T, 553 effect of subdermal implant capsules containing levonorgestrel, 281 effect of TCu 200, 281 effect of testosterone + estradiol implant (monkey), 347 effect of vaginal device releasing progesterone prematurely during proliferative phase, 177 normal cycle (monkey), 619 normal menstruating women, 329
656
JUNE
1983 VOL. 27 NO. 6
CONTRACEPTION testicular Estradiol
production
metabolic
after testosterone
clearance
rate, effect
+ estradiol
implant (monkey), 347
of testosterone
+ estradiol
implant
(monkey), 347 4-Estrene-3,17-dione, Estrogen Estrone
effect
determination,
on 176 -hydroxysteroid
level, during menstrual
Ethanol and contraceptive Ethinylestradiol
steroids,
interaction
monophasic,
Ethinylestradiol + desogestrel
sequential,
+ I-norgestrel,
effect
Ethinyl estradiol + levonorgestrel, Ethinylestradiol
effect
on biliary lipid composition regulation effect
supplementation responses
and ethanol,
interaction
on acceptability,
577
in clinical trials,
on side effects
453
and discontinuation,
465
during menstrual
on clotting
comparison
side effects
Ethynylestradiol + levonorgestrel,
effect
iron binding capacity Ethynylestradiol + levonorgestrel
Factors
significantly level,
(rat), 401 and triphasic
versions
when used for postcoital
on levels of hemoglobin,
contraception,
39
serum iron and
with ferrous fumarate,
effect
on levels of hemoglobin,
in anemic women, 311
pharmacokinetics
after morning or evening
153
level, after
Ferritin
women, 299
in anemic women, 311
Ethynyloestradiol + norethisterone,
randomised
activity
cycle of lactating
of monophasic
serum iron and iron binding capacity administration,
women with regular
439
Ethinyloestradiol + norgestrel,
effect
1, 13, 27
on plasma hormone levels,
605
function
Ethinyl oestradiol + levonorgestrel,
Expulsion,
in Mexican women, 591
in nursing women,
to LH-RH in lactating
cycles resumed,
on pituitary-ovarian
Ethynyloestradiol
577
+ norgestrel,
menstrual Ethinyl estradiol
(rat), 401
on plasma hormone levels, 577
with mestranol + norethindrone
on gonadotropin
effects
activity
on plasma hormone levels,
effect
triphasic,
of daily vitamin
Ethinyl estradiol
(dog), 431 women, 329
+ norethindrone,
comparison effect
on clotting
effect
fertility
+ levonorgestrel
Ethinyl estradiol
activity
menstruating
cycle, 409
+ desogestrel
Ethinyl estradiol
oxidoreductase
morning urine samples from normally
administration
comparative associated
evaluation
of ethynyloestradiol + norethisterone,
153
of Cu-IUD% 75
with vaginal carriage
of -E. coli, 497
of T Cu 220, 289
predictive
value in anemia development
after T Cu 220 insertion,
289
Fertility, effect
of cadmium
(rat), 521
JUNE 1983 VOL. 27 NO. 6
657
CONTRACEPTION
Fertility
effect
of cadmium + zinc (rat), 521
effect
of testosterone
regulation
+ estradiol
implant (monkey), 383
in nursing women,
copper T, 13 ethinyl estradiol + levonorgestrel, Filamentous
intrauterine
First treatment
copper corrosion,
cycle, effectiveness
First trimester
pregnancy stimulating
MLCu250 and MLCu375, 85
of oral contraceptive
termination,
dimethyl-trans-A FSH (follicle
1, 13, 27
pre-operative
’ PGEl methyl ester,
regimens,
cervical
531
dilatation
using 16,16-
339
hormone)
FSH level, during menstrual
cycle of lactating
women, 299
effect
of ethinylestradiold
+ desogestrel
monophasic,
effect
of ethinylestrsdiodl
+ desogestrel
sequential,
effect
of ethinylestradiol
+ levonorgestrel
effect
of ethinyl estradiol
+ norgestrel
577 577
triphasic,
577
during menstrual
cycle of lactating
women, 299 effect
of ethinylestradiol
+ norgestrel
effect
of ethinyl estradiol
+ norgestrel
with regular menstrual effect
of norethisterone
effect
of Nova-T, 553 of testosterone
+ estradiol
response
to LH-RH, 605
response
to LH-RH in lactating
to LH-RH, 605
to response
cycles resumed,
enanthate,
effect
to response
to LH-RH in lactating
women
605
553 implant (monkey), 347
women with regular menstrual
cycles resumed’, 605
Glucose level, effect
of subdermal
effect
of TCu 200, 281
Gonadotropin
responses resumed,
implant capsules containing
to LH-RH in lactating
on epididymis
Growth of prolactinomas,
281
women with regular menstrual
of ethinyl estradiol + norgestrel,
effect
Gossypol, clinical study of vaginal contraceptive effect
levonorgestrel,
efficacy,
cycles
605
571
(rat), 391 influence
Hand pump, use in vacuum aspiration,
of oral contraceptive
steroids,
69
63
hCG (human choriogonadotropin) hCG antagonist,
658
effect
on ovulation
(rat), 515
JUNE 1983 VOL. 27 NO. 6
CONTRACEPTION hCG vaccine
development,
a proposed standard
for laboratories,
627
hCH/LH level, effect
of norethisterone
effect
of Nova-T, 553
enanthate,
553
HDL (high density lipoprotein) HDL-cholesterol, effect
of subdermal
effect
of TCu 200, 281
Hematological
implant capsules
parameters,
interaction
containing
between
levonorgestrel,
281
ethanol and contraceptive
steroids
(rat), 401 Hematological
results,
Hematology, Hemoglobin
effect
effect
of zoapatle
of testosterone
aqueous crude extract
(rat), 255
+ estradiol
implant (monkey), 363, 383
+ levonorgestrel
in anemic women, 3!1
level,
effect
of ethynylestradiol
effect
of ethynylestradiol + levonorgestrel
with ferrous
fumarate
in anemic
women, 311 effect
of levonorgestrel-releasing
effect
of Nova-T, 473
effect
of T Cu 220, 289
effects
capsules,
473
of IUDs in anemic women, 311
Hexanic extract
of zoapatle
aqueous crude extract,
effect
on uterine
contractility
(rat, guinea pig), 267 Homogeneous
rods containing
Hormonal consequences
levonorgestrel,
release
rate, 483
of missed pills, oral contraceptive
regimens,
531
Hormone changes during placebo week, oral contraceptive
regimens,
531
17 6-Hydroxy-7
crmethyl-5-androstene-3-one (rat, hamster,
17-Hydroxyprogesterone
effect
molecular
administration
Inadvertent
pregnancies,
Indomethacin,
steroids
characteristics
Inadvertent
of vaginal device releasing
during proliferative
oxidoreductase
of different
properties
progesterone
phase, 177
activity, on testosterone
necessary
synthesis
for competitive
during very early pregnancy, oral contraceptive
use in study of morphology follicles
(RMI 12,936), endocrine
95
level, effect
prematurely 17 6-Hydroxysteroid
rabbit),
(dog), 431 inhibition,
431
oral contraceptive
regimens,
531
users, 531 and functions
of anovulatory
luteinized
(monkey), 505
Infant growth,
JUNE 1983 VOL. 27 NO. 6
659
CONTRACEPTION effect
of copper T in nursing women, 13
effect
of ethinyl e&radio1 + levonorgestrel
Inhibition
of testosterone
Injectable
contraceptive,
synthesis
medroxyprogesterone norethisterone Inorganic
acetate,
enanthate,
phosphorus
of subdermal
effect
of TCu 200, 281 factors
Intermenstrual
implant capsules
and effectiveness,
bleeding,
versions,
containing
levonorgestrel,
oral contraceptive
regimens,
281 531
of ethinyl oestradiol + levonorgestrel
comparison
and triphasic Intracellular
161
553, 591
level,
effect Interfering
in nursing women, 1,13, 27
in testis (dog), 431
distribution,
estradiol
and estrone
in endometrium
during menstrual
cycle, 409
estradiol
and estrone
in myometrium
during menstrual
cycle, 409
Intrauterine
monophasic
439
device (IUD),
copper T, 13 cu7,75, effect
ill on plasminogen
activator
activity
in uterine
tissue, 131
Lipples loop, 311 Lippes loop D, 131 MLCu250, 85 MLCu375,85 Multiload Cu250, 75 Nova-T, 473, 553 Progestasert, Saf-T-Coil,
311 131
TCu 200, 281 TCu 220, 289 TCu-220C, Ionic content,
75, 311
different
aqueous zoapatle
IPAS Modified Gynecologic
crude extracts,
239
Syringe, use in vacuum aspiration,
63
Iron binding capacity, effect
of ethynylestradiol + levonorgestrel
in anemic women, 311
effect
of ethynylestradiol
with ferrous fumarate
+ levonorgestrel
in anemic
women, 311 effects IUD (intrauterine
660
of IUDs in anemic women, 311 device)
JUNE 1983VOL. 27N0.6
CONTRACEPTION Kauradienoic effect
acid ((-)-kaura-9(ll),16-dien-19-oic on uterine
obtained Lactating
contractility
from hexanic
Lactating
(rat, guinea pig), 267
extract
of zoapatle
during menstrual
267
+ norpestrel
on pituitary-ovarian
cycle, 299
women with regular menstrual estradiol
leaves,
of ethinyl estradiol + norgestrel
women, effect function
acid),
cycles resumed,
on gonadotropin
effect
responses
of ethinyl to LH-RH, 605
Lactation, effect
of copper T, 13
effect
of ethinyl estradiol + levonorgestrel,
Laminaria
tent, preoperative
Late first trimester
cervical
abortion,
laminaria
dilatation
comparison
1,13, 27 in late first trimester,
of different
for preoperative
dilatation
prostaglandin
of cervix,
51
analogues
and
51
LDL (low density lipoprotein) LDL-cholesterol, effect
of subdermal
effect
of TCu 200, 281
Levonorgestrel
implant
capsules
containing
containing
during use of covered
rods containing
influence
levonorgestrel,
of period from application release
rates, capsules,
Levonorgestrel-containing
of tourniquet
release
rods and covered
rods, 483
281 administration,
123
administration,
123
rate, 483
levonorgestrel
covered
rods,
plasma levels during continuous
rate, 483
Levonorgestrel-containing Levonorgestrel-releasing LH (luteinizing
of blood, 123
vs. other arm, 123
homogeneous
plasma levels during continuous
Levonorgestrel-containing release
123 to withdrawal
capsules,
on clinical chemistry,
levonorgestrel
123
levonorgestrel,
sample taken from arm with implants
effect
281
level,
during use of capsules
Levonorgestrel
levonorgestrel,
homogeneous capsules,
rods, release
contraception
hormone or immunoreactive
rate, 483
after pregnancy
termination,
473
lutropin)
LH level, during menstrual effect
JUNE
cycle of lactating
women, 299
of A-LH-RH (monkey), 619
1983 VOL. 27 NO. 6
661
CONTRACEPTION
effect
of D-Trp’-LH-RH
(monkey), 619 + desogestrel
effect
of ethinylestradiol
effect
of ethinylestradiol + desogestrel
effect
of ethinylestradiol + levonorgestrel
effect
monophasic,
estradiol + norgestrel
of ethinyl
577
sequential,
577
triphasic,
577
during menstrual
cycle of lactating
women, 299 effect
of ethinyl
estradiol + norgestrel
to response
to LH-RH, 605
effect
of ethinyl
estradiol + norgestrel
to response
to LH-RH in lactating
with regular
menstrual
cycles resumed,
effect
of testosterone
effect
of vaginal device releasing
+ estradiol
implant
women
605
(monkey), 347
progesterone
prematurely
during proliferative
phase, 177 normal cycle (monkey), normal menstruating
6 19
women, 329
response
to LH-RH, 605
response
to LH-RH in lactating
women with regular
menstrual
cycles resumed,
605
LH/hCG level, effect
of norethisterone
effect
of Nova-T,
LHRH (luteinizing
enanthate,
553
553
hormone
releasing
hormone)
LHRH analogue, D-Trp’-LH-RH,
619
D-trp’-pro’-NEt-LHRH, [N-AcD-Trp”’ LH-RH stimulation,
,D-p-Cl-Phe2,D-Phe’,D-Ala? effect
in lactating Lipids and side effects, Lipoprotein
195 of ethinyl
effect
menstrual
of medroxyprogesterone
619
to gonadotropin cycles resumed,
acetate
responses 605
in Nigerian
women, 161
pattern, of subdermal
effect
of TCu 200, 281
Lippes loop, effect
implant
capsules
on levels of hemoglobin,
in anemic Lippes loop D, effect Lithospermum
-LH-RH, + norgestrel
women with regular
effect
Lithosperm
estradiol
levonorgestrel,
281
serum iron and iron binding capacity
women, 3ll
on plasminogen
(Lithospermum ruderale
containing
ruderale
plant extract
activator
activity
in uterine
tissue, 131
plant extract) (lithosperm),
effect
on thyroidal
32P
uptake (chick), 639
662
JUNE 1983 VOL. 27 NO. 6
CONTRACEF’TION Luteal phase length, anovulatory effect
luteal cycle (monkey), 505
of agonistic
Luteinization
and antagonist
of unruptured
Luteinized
anovulatory
Mechanism
of action,
follicles,
follicle
estrogen-progestogen progestogen-only
anovulatory
of LH-RH (monkey), 619 luteal cycle (monkey), 505
(monkey), 505
combinations, formulations,
Medroxyprogesterone
analogues
acetate,
531
531
effect
in Nigerian
on blood lipids and side effects
women, 161 Menses induction,
polymeric
controlled
release
vaginal delivery
system
containing
(15S)15-methyl PGP 9 a methyl ester, 141 Menstrual
bleeding,
Menstrual
cycle,
effect
effect
of vaginal device releasing
during breast-feeding,
progesterone
563
prematurely
during proliferative
phase, 177 subcellular
distribution
myometrium,
of estradiol
and estrone
in endometrium
and
409
Menstrual
cycle of lactating
Menstrual
disturbances,
of ethinyl estradiol + norgestrel
women, effect
pituitary-ovarian levonorgestrel-releasing
function,
299
capsules,
473
on
Nova-T, 473 Menstrual
flow,
effect
of levonorgestrel-releasing
effect
of Nova-T, 473
Mestranol
473
+ norethindrone,
comparison effect Metabolic
capsules,
with ethinyl estradiol
+ norethiadrone
of daily vitamin supplementation
clearance
rate of estradiol,
effect
in clinical trials, 453
on side effects of testosterone
and discontinuation, + estradiol
465
implant (monkey),
347 Metabolic
clearance
rate of testosterone,
implant 15-Methyl-PGF3
effect
of testosterone
+ estradiol
(monkey), 347
c1methyl ester,
trimester, Mexican women, effects Missed oral contraceptive
preoperative
cervical
dilatation
in late first
51 of synthetic
steroid
contraceptives
on biliary lipid composition,
591
pills,
JUNE 1983 VOL. 27 NO. 6
663
CONTRACEPTION hormonal
consequences,
risk of pregnancy, Morning or evening
531
531
administration,
norethisterone, Morning urine samples
from normally
urinary Morphology Motility
initiation
Multiload
estrogens,
of luteinized
of spermatozoa,
subcellular
menstruating
women, determination
of total
329
anovulatory
Cu250, randomized
Myometrium,
of ethynyloestradiol +
pharmacokinetics
153
follicle effect
comparative
distribution
(monkey),
505
of gossypol
on epididymis
evaluation
of Cu-IUDs,
of estradiol
and estrone
(rat), 391 75
during menstrual
cycle,409 ,D-p-CI-Phe2,D-Phe6,D-Ala101
[N-Ac-D-T&’
ovulation Naproxen-sodium,
(monkey),
danazol
folicles
Nigerian
women,
contraception,
effect
and phenytoin, enanthate,
of anovulatory when used for
on blood lipids and
activity
interaction
contraception,
(rat), 401
563
(monkey) 423 in Mexican
women,
591
553
level,
after
administration
after
postabortal
effect
on clotting
on biliary lipid composition
postabortal
acetate
during breast-feeding,
Norethisterone
Norethisterone
and functions
39
interaction
acceptability
Norethisterone effect
on
161
and ethanol,
Norethisterone,
effect
505
of medroxyprogesterone
side effects, Norethindrone
(monkey),
with ethinyloestradiol + norgestrel
compared
postcoital
(A-LH-RH),
619
use in study of morphology
luteinized Nausea,
-LH-RH
of ethynyloestradiol + norethisterone, norethisterone
of phenytoin
(monkey),
enanthate,
153
553
423
Nova-T, contraception postabortal Nulliparous
after
pregnancy
contraception,
women,
incidence
clinical
trials,
termination,
473
553 of pelvic inflammatory
disease
during Cu-7
ill
Nursing women, influence
of copper T, 13
influence
of ethinyl
estradiol + levonorgestrel
on lactation
and infant
growth,
1,13, 27
JUNE 1983VOL. 27 NO. 6
CONTRACEPTION
Onset of post-treatment
period, danazol compared
when used for postcoital Operative
complications
with ethinyloestradiol
contraception,
at vacuum aspiration,
A 2 PGEl methyl ester,
+ norgestrel
39
pre-operative
16,16_dimethyl-trans-
339
Oral contraceptive, drug interactions, effectiveness
531
and interfering
factors,
ethinylestradiol + desogestrel ethinylestradiol
+ desogestrel
sequential,
ethinyl e&radio1 + 1-norgestrel,
1,13, 27
ethinylestradiol + levonorgestrel
triphasic,
+ norethindrone
ethinyl estradiol + norgestrel,
with ferrous
ethinyl oestradiol + levonorgestrel,
453, 465
439
ethynylestradiol + levonorgestrel,
439
311 with ferrous
ethynyloestradiol + norethisterone,
fumarate,
311
153
531
mestranol + norethindrone norethisterone,
fumarate,
triphasic,
ethynylestradiol + levonorgestrel of action,
577
299, 605
ethinyl oestradiol + levonorgestrel
mechanism
577 577
591
ethinyl estradiol + levonorgestrel, ethinyl estradiol
531
monophasic,
with ferrous
fumarate,
453, 465
563
Oral contraceptive
steroids,
Oral contraceptive
users, inadvertent
influence
on development pregnancies,
or growth of prolactinomas,
69
531
OrFan weight assay, RMI 12, 936 (rat), 95 Outcome
variables,
vacuum aspiration
with electric Ovarian cycle, plasminogen Ovarian effect,
with IPAS Modified Gynecologic
pump and standard activator
progesterone
released
activity
Syringe compared
hand pump, 63 during different
prematurely
phases, 131
during proliferative
phase, 177
Ovulation, anovulatory
luteal cycle (monkey), 505
effect
of agonistic
effect
of hCG antagonist
Oxytocin,
uterine
and antagonistic
response
Parous women, incidence Pelvic inflammatory
analogues
of LH-RH (monkey), 619
(rat), 515
(Fuinea pig), 239 of pelvic inflammatory
disease,
incidence
disease during 01-7 clinical trials, 111
in clinical trials with Cu-7,111
PG (prostaglandin) Pharmacokinetic
parameters
for ethynyloestradiol,
JUNE 1983 VOL. 27 NO. 6
after
morning or eveninF administration
665
CONTRACEPTION
of ethynyloestradiol Pharmacokinetic
parameters
+ norethisterone,
for norethisterone,
153 after morning or evening administration
of ethynyloestradiol + norethisterone, Pharmacokinetics
after
morning or evening administration,
+ norethisterone, cervical Phospholipids
PGE2 methyl sulfonylamide,
dilatation
and norethisterone, level, effect
in late first trimester, interaction
of injectable
Pill dosage and unusual pill regimens, Pituitary,
ovarian and endometrial function
preoperative
51
(monkey), 423 medroxyprogesterone
effectiveness
effects,
during proliferative Pituitary-ovarian
ethynyloestradiol
153
WPhenoxy-o-17,18,19,20-tetranor Phenytoin
153
acetate,
161
of oral contraceptive
progesterone
released
regimens,
531
prematurely
phase, 17’7
during menstrual
cycle of lactating
of ethinyl estradiol + norgestrel,
women, effect
299
Plasma renin activity, effect
of ethinylestradiol
+ desogestrel
monophasic,
effect
of ethinylestradiol
+ desogestrel
sequential,
effect
of ethinylestradiol + levonorgestrel
Plasminogen Platelet
activator,
changes in uterine
count, interaction
Postabortal
between
577 577
triphasic,
577
tissue induced by IUDs, 131
ethanol and contraceptive
steroids
(rat), 401
contraception,
norethisterone
enanthate,
553
Nova-T, 553 Postcoital
contraceptive,
danazol,
39
ethinyloestradiol + norgestrel, Postcoital
test, effect
of gossypol,
Potassium
concentration,
Predictive
value of serum ferritin insertion,
effect
39 571
of gossypol on epididymis in anemia development
(rat), 391 after T Cu 220
289
Pregnancy, effect
of synthetic
inadvertent Pregnancy
666
androstane
administration
derivatives
(baboon), 201
of oral contraceptives,
531
termination,
immediate
contraception
with levonorgestrel-releasing
immediate
contraception
with Nova-T, 473
capsules,
JUNE
473
1983 VOL. 27 NO. 6
CONTRACEPTION Preoperative
cervical
dilatation
prostaglandin Pre-operative
cervical
in late first trimester,
analogues
dilatation
dimethyl-trans-A2 Progestasert,
effect
and laminaria,
in termination
of different
51
of first trimester
PGEl methyl ester,
on levels of hemoglobin,
comparison
pregnancy,
16,16-
339
serum iron and iron binding capacity
in anemic women, 311 ProgestationaUantiprogestational Progesterone
activity,
effect
on RMI 12,936 (rat, rabbit),
95
level,
anovulatory
luteal cycle (monkey), 505
during menstrual
cycle of lactating
women, 299
effect
of A-LH-RH (monkey),
619
effect
of D-Trp’-LH-RH
(monkey), 619
effect
of ethinylestradiol
+ desogestrel
monophasic,
effect
of ethinylestradiol
+ desogestrel
sequential,
effect
of ethinylestradiol
+ levonorgestrel
effect
of ethinyl estradiol + norgestrel
577 577
triphasic,
577
during menstrual
cycle of lactating
women, 299 effect
of norethisterone
effect
of Nova-T, 553
enanthate,
effect
of synthetic
effect
of vaginal device releasing
androstane
553
derivatives
(baboon), 201
progesterone
prematurely
during proliferative
phase, 177 normal cycle (monkey), 619 Progesterone
released
prematurely
endometrial Prolactin
during proliferative
effects,
phase, pituitary,
ovarian and
177
level,
during menstrual
cycle, 299, 605
during menstrual
cycle of lactating
299, 605
women,
effect
of ethinylestradiol + desogestrel
monophasic,
effect
of ethinylestradiol + desogestrel
sequential,
effect
of ethinylestradiol
effect
of ethinyl estradiol + norgestrel,
effect
of ethinyl estradiol
+ levonorgestrel + norgestrel
triphasic,
577 577 577
605 during-menstrual
cycle of lactating
women, 299 effect
of ethinyl estradiol + norgestrel cycles resumed,
JUNE 1983 VOL. 27 NO. 6
in lactating
women with regular menstrual
605
667
CONTRACEPTION Prolactinomas, Proliferative
influence
of oral contraceptive
phase premature endometrial
Proposed
standard
Prostaglandin
exposure
effects,
steroids
on development
to progesterone,
pituitary,
or growth, 69
ovarian and
177
for laboratories
involved in development
of hCG vaccines,
627
analogue,
9-deoxo-l6,l6-dimethyl-9-methylene 16,16_dimethyl-trans
PGE2, 51
A2PGEl methyl ester,
15-methyl PGE2 a methyl ester,
51, 339
51
16-phenoxy- w-17,18,19,20-tetranor
PGE2 methyl sulfonylamide,
51
(15S)15-methyl PGFZc, methyl ester, 141 Prostaglandin
analogues,
comparison
first trimester Protein
pattern
Quatelet’s
Release
for preoperative
abortion,
of cauda fluid, effect
dilatation
of cervix in late
51 of gossypol on epididymis
(rat), 391
index,
effect
of ethinyl estradiol + 1-norgestrel,
effect
of norethisterone
enanthate,
rates of levonorgestrel,
591
591
capsules,
homogeneous
rods and covered
rods, 483
Removals, levonorgestrel-releasing
capsules,
473
Nova-T, 473 randomised Reproductive
comparative
evaluation
of Cu-IUDs, 75
organ weights,
effect
of cadmium
effect
of cadmium + zinc (rat), 521
Reproductive
tissues,
Risk of pregnancy,
(rat), 521
effect
of testosterone
+ estradiol
missed oral contraceptive
RMI 12,936 (176 -hydroyx-7o
implant (monkey), 363
pills, 531
-methyl-5-androstene-3-one)
(15S)15-methyl PGP2 Q free acid and methyl ester, extraction purification
and quantitation,
(15S)15-methyl PGP2 cI level in plasma, polymeric delivery system,
Saf-T-Coil,
effect
Second trimester
on plasminogen
release
controlled
release
and second trimester
activator
termination,
system containing
668
polymeric
for menses induction
pregnancy
controlled
vaginal
141
(15S)15-methyl PGF2 c( methyl ester, system
from plasma,
141
activity
polymeric
vaginal delivery
pregnancy
termination,
in uterine tissue, 131 controlled
(15S)15-methyl PGP20
release
vaginal delivery
methyl ester, 141
JUNE 1983 VOL. 27 NO. 6
141
CONTRACEPTION Semen characteristics,
effect
of testosterone
+ estradiol
implant (monkey), 383
Serum iron level, effect
of ethynylestradiol
+ levonorgestrel
in anemic women, 311
effect
of ethynylestradiol
+ levonorgestrel
with ferrous fumarate
in
anemic women, 311 effects
of IUDs in anemic women, 311
Sex hormone binding globulin, effect
of ethinylestradiol
effect
of ethinylestradiol + desogestrel
+ desogestrel
effect
of ethinylestradiol
monophasic, sequential,
+ levonorgestrel
577 57’7
triphasic,
577
Side effects, comparison
of different
cervical
prostaglandin
dilatation
analogues
in late first trimester
of ethinyl oestradiol + levonorgestrel
comparison
and laminaria abortion,
for preoperative
51
monophasic
and triphasic
versions,
439 of mestranol + norethindrone
comparison
danazol compared
with ethinyloestradiol
contraception, effect
of vitamin
injectable
and ethinyl estradiol + norethindrone, + norgestrel
453
when used for postcoital
39
supplementation
medroxyprogesterone
levonorgestrel-releasing
during oral contraceptive acetate,
capsules,
use, 465
161
473
Nova-T, 473 pre-operative
16,16-dimethyl-trans-A
Sodium concentration, Somatic
effect
tissue responses,
Sperm concentration,
effect
effect
2 PGEl methyl ester,
of gossypol on epididymis of testosterone
+ estradiol
of gossypol on epididymis
339
(rat), 391 implant (monkey), 363
(rat), 391
Sperm motility effect
of gossypol,
effect
of gossypol on epididymis
571 (rat), 391
Sperm population, effect
of cadmium (rat), 521
effect
of cadmium + zinc (rat), 521
Sperm production, Spinnbarkeit,
effect
of testosterone
normal menstruating
Stability
of solutions,
Steroids,
effect
assessment
on testosterone
JUNE 1983VOL.27N0.6
+ estradiol
implant (monkey), 347
women, 329 for D-trp’-pro’-NEt-LHRH, synthesis
195
in testis (dog), 431
669
CONTRACEPTION Subcellular
distribution,
estradiol
during menstrual Subdermal
in endometrium
and myometrium
implant,
capsules
containing
capsules
releasing
covered
rods containing
covered
rods releasing
homogeneous
levonorgestrel,
123
levonorgestrel,
rods releasing
on clinical
483
levonorgestrel,
483
levonorgestrel,
capsules,
polydimethylsiloxane
TCu 200, effect
123, 281
levonorgestrel,
levonorgestrel-releasing Subdermal
and estrone
cycle, 409
implant,
chemistry,
483
473 testosterone
+ estradiol
(monkey), 347, 363, 383
281
T Cu 220, effect
of serum ferritin
predictive
and other hematological
value of serum ferritin
parameters,
in anemia development
289
after insertion,
289
TCu-220C, effect
on levels of hemoglobin,
serum iron and iron binding capacity
in
anemic women, 311 randomized Termination
rates,
comparative
evaluation
random&d
comparative
on Cu-IUDs, 75 evaluation
of Cu-IUDs, 75
Terminations, of mestranol + norethindrone
comparison
norethindrone, effect Testis,
of vitamin
inhibition
Testis function, Testosterone
somatic Testosterone
during oral contraceptive
synthesis
of testosterone
by steroids
+ estradiol
use, 465
(dog), 431
implant (monkey), 347
+ estradiol,
contraceptive effect
453
supplementation
of testosterone effect
and ethinyl estradiol +
on testis
efficacy function
tissue responses blood production
(monkey), 383 (monkey), 347 (monkey), 363 rate, effect
of testosterone
+ estradiol
implant
(monkey), 347 Testosterone
670
level,
effect
of cadmium
effect
of cadmium + zinc (rat), 521
(rat), 521
effect
of ethinylestradiol
+ desogestrel
monophasic,
effect
of ethinylestradiol
+ desogestrel
seqential,
effect
of ethinylestradiol
+ levonorgestrel
triphasic,
577
577 577
JUNE 1983VOL. 27N0.6
CONTRACEPTION
effect
of subdermal
effect
of TCu 200, 281
effect
of testosterone
testicular Testosterone
implant
+ estradiol
production
metabolic
capsules
after
clearance
containing
levonorgestrel,
281
implant (monkey), 347
testosterone
+ estradiol
implant (monkey), 347
rate, effect
of testosterone
+ estradiol
implant
(monkey), 347 Testosterone
synthesis
Thyroid stimulating
inhibition
in testis (dog), 431
hormone level,
effect
of subdermal
effect
of TCu ZOO,281
implant capsules
containing
levonorgestrel,
281
Thyroid weight, effect
of lithosperm
(chick), 639
effect
of lithosperm
and propyithiouracil
Thyroidal
(chick), 639
32P uptake,
effect
of lithosperm
(chick), 639
effect
of lithosperm
and propylthioiuracil
effect
of lithosperm
and thyroid-stimulating
Thyroxine
hormone (chick), 639
level,
effect
of subdermal
effect
of TCu 200, 281
Time of use and corrosion, Total urinary estrogens, normally Toxicological Traditional
studies,
implant capsules
containing
levonorgestrel,
281
MLCu250 and MLCu375 IUDs, 85
determination menstruating zoapatle
in morning urine samples from women, 329
aqueous crude extract
remedy from Mexico, zoapatle,
Triglycerides
(rat, dog), 255
211
level,
effect
of injectable
medroxyprogesterone
effect
of subdermal
implant capsules
effect
of TCu 200,281
Triiodothyronine
acetate,
161
containing
levonorgestrel,
281
implant capsules containing
levonorgestrel,
281
level,
effect
of subdermal
effect
of TCu 200, 281
Triphasic
(chick), 639
ethinyl oestradiol + levonorgestrel, on acceptability,
Urine samples collected
comparison
to monophasic
in the morning from normally menstruating
determination
version
439 of total urinary estrogens,
JUNE 1983VOL. 27 NO. 6
women,
329
671
CONTRACEPTION Use-effectiveness, Uterine
of mestranol + norethindrone
comparison
norethindrone,
and ethinyl estradiol +
453
contractility, effect
of hexanic
extract
of zoapatle
aqueous crude extract
(rat,
guinea pig), 267 effect
of kauradienoic
effect
of zoapatle
Uterine
contractions,
Uterine
response,
acid (rat, guinea pig), 267
aqueous crude extract
increase
associated
dialysed
extract
oxytocin
(guinea pig), 239
Uterine
tissue,
of zoapatle
changes
crude extract
of plasminogen
potency,
Uterotonic
potency
of several
various lvlontanoa species,
Uterotonic
potency
of wild and cultivated
Uterotonic
properties,
Vacuum aspiration,
specimens
zoapatle
and standard
of zoapatle
(guinea pig), 239
(guinea pig), 239
of RMI 12,936 (rat), 95 Syringe compared
with electric
pump
hand pump, 63
of abortifacient,
containing
induced by IUDs, 131
(guinea pig), 239
specimens
effect
211
227
of zoapatle
IPAS Modified Gynecologic
Vaginal administration
activity
aqueous crude extract
activity,
of zoapatle,
(guinea pig), 239
activator
Uterotonic
Uterotrophic/estrogenic
(rat, guinea pig, dog), 267
with aaueous plant extract
polymeric
(lSS)lS-methyl
of -E. -f Coli to contraceptive
controlled
PGF2 u methyl ester,
release
delivery
system
141
Vaginal colonization relation
significantly Vaginal contraceptive, Vaginal device,
factors,
gossypol
releasing
effect
discontinuation,
Withdrawal
bleeding,
Zoapatle
a traditional
comparison
side effects
and
tomentosa remedy
+ norgestrel
when used for
39
of ethinyl oestradiol
versions,
aqueous plant extract
672
177
with ethinyloestradiol
on cadmium-induced
(Montanoa
acid gel, 57 1
on oral contraceptive
contraception,
and triphasic Zinc, effect
497
497
465
danazol compared postcoital
acetic
progesterone,
Vitamin supplementation, Vomiting,
methods,
associated
+ levonorgestrel
monophasic
439
sterility
(rat), 521
(Cerv.) s.s.p. tomentosa
(Funk.)),
from Mexico, ‘211 associated
biological
and uterotonic
biological
observations,
with increase
properties
in uterine
contractions,
of aqueous plant extract
211
(guinea pig), 239
211
JUNE 1983 VOL. 27 NO. 6
CONTRACEPTION botanical clinical effect
and ecological observations,
of hexanic
determinants,
227
211
extract
(kauradienoic
acid) upon uterine
contracility
(rat,
guinea pig, dog), 267 history,
211
isolation
of active principle(s),
toxicological Zoapatle
211
and clinical studies of aqueous crude extract
(rat, dog), 255
aoueous crude extract,
effect
on uterine
contractility
effect
on uterine
strips of different
JUNE 1983 VOL. 27 NO. 6
(rat, guinea pig, dog), 267 animal species,
239
673
INDEX TO VOLUME 27 SUBJECT INDEX
A-LH-RH (IN-A~-D-T~$~~ ,D-p-Cl-Phe2D-Phe6,D-Ala101 Abortifacient
effect,
synthetic
androstane
derivatives
-LH-RP) (baboon), 201
Acceptability, comparison
of ethinyl oestradiol
triphasic norethisterone Accidental
versions,
+ levonoreestrel
during breast-feeding,
pregnancy,
monophasic
and
439
randomised
563
comparative
evaluation
of Cu-IIJDs, 75
1B-Acetoxy-l7a-ethinyl-l7-hydroxy-l8-methyl-4-ostren-3-on,
abortifacient
effect
(baboon), 201 16-178-Acetoxy-18-methyl-4-ostren-3-on, Age, effect Agonistic
on incidence
abortifacient
of pelvic inflammatory
analogue of LH-RH, D-Trp’-LH-RH,
Aldosterone
effect
disease during Cu-7 clinical
trials, ill
619
level,
effect
of ethinylestradiol
+ desogestrel
monophasic,
effect
of ethinylestradiol
+ desogestrel
sequential,
effect
of ethinylestradiol
+ levonoreestrel
AndrogenWantiandrogenic Androstane
(baboon), 201
derivatives,
5-Androstene-3,
activity,
l’l-dione, effect
Anemia development
effect
abortifacient
577 577
triphasic,
577
of RMI 12,936 (rat), 95
effect
(baboon), 201
on 178-hydroxysteroid
after T Cu 220 insertion,
predictive
oxidoreductase
activity
(dog), 431
value of serum ferritin,
289
Anemic women, effects
of ethynylestradiol
+ levonorpestrel
iron and iron binding capacity, effects
of ethynylestradiol of hemoglobin,
effects
on levels of hemoglobin,
serum
311
+ levonorgestrel
with ferrous
fumarate
serum iron and iron binding capacity,
of IUDs on levels of hemoglobin,
on levels
311
serum iron and iron binding capacity,
Anovulatory
luteal cycles (monkey), 505
Antagonistic
activity,
Antagonistic
analogue of LH-RH, [N-Ac-D-Trp1y3 ,D-p-C1-Phe2,D-Phe6,D-Ala101
deglycosylated
311
hCG (rat), 515 -
LH-RH, 619 Anti-hCG
antiserum,
antibody
titers
using the recommended
binding of hormones
and subunits,
JUNE 1983VOL. 27 NO. 6
standard
assay, 627
627
651
CONTRACEPTION characterization,
6’27
determination Antifertility
of isoantibody
Antigonadotropic
activity,
Antirwogestetional
effect
steroid,
Asialo hCG, effect
RMI 12,936, 95 activity,
effect
of RMI 12,936 (rat), 95
on action of hCG (rat), 515
bCH (baboon chorionic effect
Bile lithogenic
95
of RMI 12,936 (rat), 95
Antiuterotrophic/antiestroPedic
bCH level,
class, 627
assay, RMI 12,936 (hamster),
gonadotropin)
of synthetic
androstane
derivative
(baboon), 201
index,
effect
of ethinyl estradiol
effect
of norethisterone
+ I-norgestrel, enanthate,
591
591
Biliary lipid composition, effect
of ethinyl estradiol
effect
of norethisterone
Biological
activity
Biological
observations,
Biological
properties,
+ I-norqestrel, enanthate,
of Wtrp’-pro’
Bleeding duration, Bleeding patterns,
aaueous crude extract
versions,
effect
assessment
for stability
of solutions,
195
211 (guinea pip), 239
of ethinyl oestradiol + levonorgestrel
comparison
triphasic
591
-NEt-LHRH,
zoapatle, zoaoatle
591
monophasic
and
439
of norethisterone
during breast-feeding,
563
Blood chemistry, effect
of testosterone
effect
of zoapatle
Blood clotting,
effect
+ estradiol
implant (monkey), 363, 383
aqueous crude extract
of testosterone
(rat), 255
+ estradiol
implant (monkey\,
363
Blood loss at vacuum aspiration, comparison
of different
cervical pre-operative
prostaglandin
dilatation
analowes
in late first trimester
16,16-dimethyl-trans-
and laminaria abortion,
A~PGE~ methyl ester,
for preoperative
51 339
Blood pressure, comparison
of mestranol + norethindrone
effect
of levonorgestrel-releasing
effect
of Nova-T, 473
Blood production
rate of estradiol,
Blood production
rate of testosterone,
and ethipyl estradiol + norethindrone,
capsules,
effect
of testosterone
effect
453
473 + estradiol
of testosterone
implant (monkey) 347
+ estradiol
implant
(monkey), 347
652
JUNE 1983 VOL. 27 NO. 6
CONTRACEPTION Body weight, of mestranol + norethindrane
comparison effect
of levonorgestrel-releasing
effect
of lithosperm
(chick), 639
effect
of lithosperm
and propylthiouracil
effect
of Nova-T, 473
effect
of zoapatle
Botanical
and ecological
and ethinql estradiol
capsules,
453
473
(chick), 639
aoueous crude extract determinants,
+ norethirdrone,
(rat, dog:), 255
zoapatle,
227
Breast-feeding, acceptability effect
of norethisterone,
of oral contraceptive
Breast-feeding
duration,
Cadmium-induced
sterility,
Capsules containing
effect
of zirc (rat), 521
plasma levels during continuous levonorgestrel,
Caude epididymides,
effect
dilatation
contraception
administration,
123
enalogues
in termination
abortion,
and laminaria,
Cervical
dilatation
Cervical
mucus changes,
of first trimester
Cervical
state at time of vacuum aspiration,
A 2 PGEl methyl ester, enovulatory
A ’ PGEl methyl ester, Characterization
after pregnancy
termination,
473
of gossypol (rat), 391
in late first trimester
prosteglandin
Cholesterol
563
rate, 483
Capsules releasing Cervical
531
of norethisterone,
levonorgestrel,
levonorgestrel release
effect
563 regimens,
comparison
of different
51 pregnancy,
16,16-dimethyl-trens-
339 luteal cycle (monkey), 505 pre-operative
16,16-dimethyl-trens-
339
of e human anti-hCG
antiserum,
627
level,
effect
of injectable
medroxyprogesterone
effect
of subdermal
implant capsules
effect
of TCu 200, 281
Chrometogrephic
acetate,
containing
profile of D-trp’-pro’-NEt-LHPH,
161 levonorpestrel,
assessment
281
for stability
of solutions,
195 Clinical chemistry
tests,
effect
of subdermal
implant capsules
effect
of TCu 200, 281
containing
levonorgestrel,
281
Clinical date, first trimester delivery
JUNE
pregnancy
termination
system containing
1983 VOL. 27 NO. 6
using polymeric
controlled
release
vaginal
(15S)15-methyl PGF20 methyl ester, 141
653
CONTRACEPTION second trimester
pregnancy
vaginal delivery Clinical factors
influencing
Clinical observations, Clinical studies, Clotting
pill efficacy,
zoapatle,
zoapatle
termination
using polymeric
system containing
controlled
(15S)15-methyl PGF2u
release
methyl ester,
141
531
‘211
aoueous crude extract
(rat, dog), 255
activity, interaction
between
ethanol and ethinyl estradiol
interaction
between
ethanol and norethindrone
Comparative
evaluation
Complications
of copper 7, Multiload copper 250 and T copper-220C
after discharge methyl ester,
Compounds
isolated
(rat), 401
(rat), 401
from hospital,
pre-operative
IUPs, 75
16,16-dimethyl-trans-A
‘PGEl
339
from zoapatle,
211
Continuation, levonorgestrel-releasing
capsules,
473
Nova-T, 473 Continuation/withdrawal, and triphasic Continuation
versions,
of mestranol
of vitamin supplementation efficacy,
testosterone
Contraceptive
methods,
prevalence
Contragestative
effects,
Copper corrosion, Copper T, fertility Corrosion Cortisol
Cortisol
and ethinyl estradiol
during oral contraceptive
+ estradiol
453
use, 465
implant (monkey), 383
rate of vaginal colonization
RMI 12,936 (hamster),
+ norethindrone,
of -E. __ coli, 497
95
MLCu250 and MLCu375 IUDs, 85 regulation
in nursing women, 13
and time of use, MLCu250 and MLCu375 IUDs, 85 of fiIamentous
intrauterine
copper, MLCu250 and MLCu375, 85
binding globulin level, effect
of ethinplestradiol
+ desopestrel
monophasic,
effect
of ethinylestradiol
+ desogestrel
seouential,
effect
of ethinylestradiol
+ levonorgestrel
effect
of ethinylestradiol
+ desogestrel
effect
of ethinylestradiol + desogestrel
effect
of ethinylestradiol
effect
of subdermal
effect
of TCu 200, 281
577 577
triphasic,
577
monophasic,
577
level,
Covered rods containing
654
439
+ norethindrone
Contraceptive
Corrosion
monophasic
rate,
comparison effect
of ethinyl oestradiol + levonorgestrel
comparison
+ levonorgestrel
sequential,
577
triphasic,
implant capsules containing
577
levonorgestrel,
28 1
levonorgestrel,
JUNE
1983 VOL. 27 NO. 6
CONTRACEPTION levonorgestrel release
plasma levels during continuous
administration,
123
rate, 483
cu-7, incidence
of pelvic inflammatory
randomised
comparative
disease in clinical trials,
evaluation
111
of Cu-IUDs, 75
Cycle length, anovulatory
luteal cycle (monkey), 505
comparison
of ethinyl oestradiol
versions, effect
of agonistic
D-Trp’-LH-RH,
effect
and antagonistic
on ovulation
D-trp’-pro’-NEt-LHRH,
hCG, effect
of stability
on ovulation
of prolactinomas,
20 c1-Dihydroprogesterone
influence
preoperative
in
steroids,
69
progesterone
phase, 177
abortion,
comparison
of first trimester
pregnancy,
of different
prostaglandin
16,16-dimethyl-
339
’ PGEl methyl ester, cervical
dilatation
cervical
Duration of use, effect
effect
regimens,
51
of first trimester
pregnancy,
339
563
531
of norethisterone,
on incidence
clinical trials,
in termination
during breast-feeding,
oral contraceptive
Duration of breast-feeding,
in late first trimester,
dilatation
norethisterone
Drug interactions,
dilatation
51
A2 PGEl methyl ester,
pre-operative Discontinuation,
cervical
of vaginal device releasing
and laminaria,
of cervix in termination
16,16-Dimethyl-trans-A
39
of oral contraceptive
of cervix in late first trimester
trans-
195
(rat), 515
during proliferative
analogues
of solutions, contraception,
51
level, effect
prematurely
Dilatation
and triphasic
of LH-RH (monkey), 619
PGE2, preoperative
late first trimester,
Dilatation
analogues
when used for postcoital
9-Deoxo-16,16-dimethyl-9-methylene Development
monophasic
(monkey), 619
assessment
Danazol, side effects Deglycosylated
+ levonorgestrel
439
563
of pelvic inflammatory
disease during Cu-7
111
Dysmenorrhea, effect
of levonorgestrel-releasing
effect
of Nova-T, 473
capsules,
473
E. coli vaginal colonization, significantly associated factors, 497 -Early first trimester pregnancy termination, polymeric controlled release delivery
JUNE
system containing
1983 VOL. 27 NO. 6
(15S)15-methyl
vaginal
PGF2 o methyl ester,
141
655
CONTRACEPTION Ecological and botanical determinants, zoapatle, 227 Effectiveness Efficacy,
and interfering factors, oral contraceptive regimens, 531
comparison of ethinyl oestradiol + levonorgestrel monophasic and triphasic versions, 439
Ejaculate volume, effect of testosterone + estradiol implant (monkey), 363 Electric pump, use in vacuum aspiration, 63 Endocrine properties, effect of RMI 12,936 (rat, hamster, rabbit), 95 Endometrial effect,
progesterone released prematurely during proliferative phase, 177
Endometrial plasminogen activator activity, effect of IUDs, 131 Endometrium, subcellular distribution of estradiol and estrone during menstrual cycle, 409 Epididymis, effect of gossypol (rat), 391 Estradiol + testosterone, contraceptive
efficacy
(monkey), 383
effect on testis function (monkey), 347 somatic tissue responses (monkey), 363 Estradiol and estrone, subcellular distribution in endometrium and myometrium during menstrual cycle, 409 Estradiol blood production rate, effect of testosterone + estradiol implant (monkey), 347 Estradiol level, during menstrual cycle, 409 during menstrual cycle of lactating women, 299 effect of A-LH-RH (monkey), 619 effect of D-Trp’-LH-RH
(monkey), 619
effect of ethinylestradiol + desogestrel monophasic, 577 effect of ethinylestrediol + desogestrel sequential, 577 effect of ethinylestradiol + levonorgestrel triphasic, 577 effect of ethinyl estradiol + norgestrel during menstrual cycle of lactating women, 299 effect of norethisterone enanthate, 553 effect of Nova-T, 553 effect of subdermal implant capsules containing levonorgestrel, 281 effect of TCu 200, 281 effect of testosterone + estradiol implant (monkey), 347 effect of vaginal device releasing progesterone prematurely during proliferative phase, 177 normal cycle (monkey), 619 normal menstruating women, 329
656
JUNE
1983 VOL. 27 NO. 6
CONTRACEPTION testicular Estradiol
production
metabolic
after testosterone
clearance
rate, effect
+ estradiol
implant (monkey), 347
of testosterone
+ estradiol
implant
(monkey), 347 4-Estrene-3,17-dione, Estrogen Estrone
effect
determination,
on 176 -hydroxysteroid
level, during menstrual
Ethanol and contraceptive Ethinylestradiol
steroids,
interaction
monophasic,
Ethinylestradiol + desogestrel
sequential,
+ I-norgestrel,
effect
Ethinyl estradiol + levonorgestrel, Ethinylestradiol
effect
on biliary lipid composition regulation effect
supplementation responses
and ethanol,
interaction
on acceptability,
577
in clinical trials,
on side effects
453
and discontinuation,
465
during menstrual
on clotting
comparison
side effects
Ethynylestradiol + levonorgestrel,
effect
iron binding capacity Ethynylestradiol + levonorgestrel
Factors
significantly level,
(rat), 401 and triphasic
versions
when used for postcoital
on levels of hemoglobin,
contraception,
39
serum iron and
with ferrous fumarate,
effect
on levels of hemoglobin,
in anemic women, 311
pharmacokinetics
after morning or evening
153
level, after
Ferritin
women, 299
in anemic women, 311
Ethynyloestradiol + norethisterone,
randomised
activity
cycle of lactating
of monophasic
serum iron and iron binding capacity administration,
women with regular
439
Ethinyloestradiol + norgestrel,
effect
1, 13, 27
on plasma hormone levels,
605
function
Ethinyl oestradiol + levonorgestrel,
Expulsion,
in Mexican women, 591
in nursing women,
to LH-RH in lactating
cycles resumed,
on pituitary-ovarian
Ethynyloestradiol
577
+ norgestrel,
menstrual Ethinyl estradiol
(rat), 401
on plasma hormone levels, 577
with mestranol + norethindrone
on gonadotropin
effects
activity
on plasma hormone levels,
effect
triphasic,
of daily vitamin
Ethinyl estradiol
(dog), 431 women, 329
+ norethindrone,
comparison effect
on clotting
effect
fertility
+ levonorgestrel
Ethinyl estradiol
activity
menstruating
cycle, 409
+ desogestrel
Ethinyl estradiol
oxidoreductase
morning urine samples from normally
administration
comparative associated
evaluation
of ethynyloestradiol + norethisterone,
153
of Cu-IUD% 75
with vaginal carriage
of -E. coli, 497
of T Cu 220, 289
predictive
value in anemia development
after T Cu 220 insertion,
289
Fertility, effect
of cadmium
(rat), 521
JUNE 1983 VOL. 27 NO. 6
657
CONTRACEPTION
Fertility
effect
of cadmium + zinc (rat), 521
effect
of testosterone
regulation
+ estradiol
implant (monkey), 383
in nursing women,
copper T, 13 ethinyl estradiol + levonorgestrel, Filamentous
intrauterine
First treatment
copper corrosion,
cycle, effectiveness
First trimester
pregnancy stimulating
MLCu250 and MLCu375, 85
of oral contraceptive
termination,
dimethyl-trans-A FSH (follicle
1, 13, 27
pre-operative
’ PGEl methyl ester,
regimens,
cervical
531
dilatation
using 16,16-
339
hormone)
FSH level, during menstrual
cycle of lactating
women, 299
effect
of ethinylestradiold
+ desogestrel
monophasic,
effect
of ethinylestrsdiodl
+ desogestrel
sequential,
effect
of ethinylestradiol
+ levonorgestrel
effect
of ethinyl estradiol
+ norgestrel
577 577
triphasic,
577
during menstrual
cycle of lactating
women, 299 effect
of ethinylestradiol
+ norgestrel
effect
of ethinyl estradiol
+ norgestrel
with regular menstrual effect
of norethisterone
effect
of Nova-T, 553 of testosterone
+ estradiol
response
to LH-RH, 605
response
to LH-RH in lactating
to LH-RH, 605
to response
cycles resumed,
enanthate,
effect
to response
to LH-RH in lactating
women
605
553 implant (monkey), 347
women with regular menstrual
cycles resumed’, 605
Glucose level, effect
of subdermal
effect
of TCu 200, 281
Gonadotropin
responses resumed,
implant capsules containing
to LH-RH in lactating
on epididymis
Growth of prolactinomas,
281
women with regular menstrual
of ethinyl estradiol + norgestrel,
effect
Gossypol, clinical study of vaginal contraceptive effect
levonorgestrel,
efficacy,
cycles
605
571
(rat), 391 influence
Hand pump, use in vacuum aspiration,
of oral contraceptive
steroids,
69
63
hCG (human choriogonadotropin) hCG antagonist,
658
effect
on ovulation
(rat), 515
JUNE 1983 VOL. 27 NO. 6
CONTRACEPTION hCG vaccine
development,
a proposed standard
for laboratories,
627
hCH/LH level, effect
of norethisterone
effect
of Nova-T, 553
enanthate,
553
HDL (high density lipoprotein) HDL-cholesterol, effect
of subdermal
effect
of TCu 200, 281
Hematological
implant capsules
parameters,
interaction
containing
between
levonorgestrel,
281
ethanol and contraceptive
steroids
(rat), 401 Hematological
results,
Hematology, Hemoglobin
effect
effect
of zoapatle
of testosterone
aqueous crude extract
(rat), 255
+ estradiol
implant (monkey), 363, 383
+ levonorgestrel
in anemic women, 3!1
level,
effect
of ethynylestradiol
effect
of ethynylestradiol + levonorgestrel
with ferrous
fumarate
in anemic
women, 311 effect
of levonorgestrel-releasing
effect
of Nova-T, 473
effect
of T Cu 220, 289
effects
capsules,
473
of IUDs in anemic women, 311
Hexanic extract
of zoapatle
aqueous crude extract,
effect
on uterine
contractility
(rat, guinea pig), 267 Homogeneous
rods containing
Hormonal consequences
levonorgestrel,
release
rate, 483
of missed pills, oral contraceptive
regimens,
531
Hormone changes during placebo week, oral contraceptive
regimens,
531
17 6-Hydroxy-7
crmethyl-5-androstene-3-one (rat, hamster,
17-Hydroxyprogesterone
effect
molecular
administration
Inadvertent
pregnancies,
Indomethacin,
steroids
characteristics
Inadvertent
of vaginal device releasing
during proliferative
oxidoreductase
of different
properties
progesterone
phase, 177
activity, on testosterone
necessary
synthesis
for competitive
during very early pregnancy, oral contraceptive
use in study of morphology follicles
(RMI 12,936), endocrine
95
level, effect
prematurely 17 6-Hydroxysteroid
rabbit),
(dog), 431 inhibition,
431
oral contraceptive
regimens,
531
users, 531 and functions
of anovulatory
luteinized
(monkey), 505
Infant growth,
JUNE 1983 VOL. 27 NO. 6
659
CONTRACEPTION effect
of copper T in nursing women, 13
effect
of ethinyl e&radio1 + levonorgestrel
Inhibition
of testosterone
Injectable
contraceptive,
synthesis
medroxyprogesterone norethisterone Inorganic
acetate,
enanthate,
phosphorus
of subdermal
effect
of TCu 200, 281 factors
Intermenstrual
implant capsules
and effectiveness,
bleeding,
versions,
containing
levonorgestrel,
oral contraceptive
regimens,
281 531
of ethinyl oestradiol + levonorgestrel
comparison
and triphasic Intracellular
161
553, 591
level,
effect Interfering
in nursing women, 1,13, 27
in testis (dog), 431
distribution,
estradiol
and estrone
in endometrium
during menstrual
cycle, 409
estradiol
and estrone
in myometrium
during menstrual
cycle, 409
Intrauterine
monophasic
439
device (IUD),
copper T, 13 cu7,75, effect
ill on plasminogen
activator
activity
in uterine
tissue, 131
Lipples loop, 311 Lippes loop D, 131 MLCu250, 85 MLCu375,85 Multiload Cu250, 75 Nova-T, 473, 553 Progestasert, Saf-T-Coil,
311 131
TCu 200, 281 TCu 220, 289 TCu-220C, Ionic content,
75, 311
different
aqueous zoapatle
IPAS Modified Gynecologic
crude extracts,
239
Syringe, use in vacuum aspiration,
63
Iron binding capacity, effect
of ethynylestradiol + levonorgestrel
in anemic women, 311
effect
of ethynylestradiol
with ferrous fumarate
+ levonorgestrel
in anemic
women, 311 effects IUD (intrauterine
660
of IUDs in anemic women, 311 device)
JUNE 1983VOL. 27N0.6
CONTRACEPTION Kauradienoic effect
acid ((-)-kaura-9(ll),16-dien-19-oic on uterine
obtained Lactating
contractility
from hexanic
Lactating
(rat, guinea pig), 267
extract
of zoapatle
during menstrual
267
+ norpestrel
on pituitary-ovarian
cycle, 299
women with regular menstrual estradiol
leaves,
of ethinyl estradiol + norgestrel
women, effect function
acid),
cycles resumed,
on gonadotropin
effect
responses
of ethinyl to LH-RH, 605
Lactation, effect
of copper T, 13
effect
of ethinyl estradiol + levonorgestrel,
Laminaria
tent, preoperative
Late first trimester
cervical
abortion,
laminaria
dilatation
comparison
1,13, 27 in late first trimester,
of different
for preoperative
dilatation
prostaglandin
of cervix,
51
analogues
and
51
LDL (low density lipoprotein) LDL-cholesterol, effect
of subdermal
effect
of TCu 200, 281
Levonorgestrel
implant
capsules
containing
containing
during use of covered
rods containing
influence
levonorgestrel,
of period from application release
rates, capsules,
Levonorgestrel-containing
of tourniquet
release
rods and covered
rods, 483
281 administration,
123
administration,
123
rate, 483
levonorgestrel
covered
rods,
plasma levels during continuous
rate, 483
Levonorgestrel-containing Levonorgestrel-releasing LH (luteinizing
of blood, 123
vs. other arm, 123
homogeneous
plasma levels during continuous
Levonorgestrel-containing release
123 to withdrawal
capsules,
on clinical chemistry,
levonorgestrel
123
levonorgestrel,
sample taken from arm with implants
effect
281
level,
during use of capsules
Levonorgestrel
levonorgestrel,
homogeneous capsules,
rods, release
contraception
hormone or immunoreactive
rate, 483
after pregnancy
termination,
473
lutropin)
LH level, during menstrual effect
JUNE
cycle of lactating
women, 299
of A-LH-RH (monkey), 619
1983 VOL. 27 NO. 6
661
CONTRACEPTION
effect
of D-Trp’-LH-RH
(monkey), 619 + desogestrel
effect
of ethinylestradiol
effect
of ethinylestradiol + desogestrel
effect
of ethinylestradiol + levonorgestrel
effect
monophasic,
estradiol + norgestrel
of ethinyl
577
sequential,
577
triphasic,
577
during menstrual
cycle of lactating
women, 299 effect
of ethinyl
estradiol + norgestrel
to response
to LH-RH, 605
effect
of ethinyl
estradiol + norgestrel
to response
to LH-RH in lactating
with regular
menstrual
cycles resumed,
effect
of testosterone
effect
of vaginal device releasing
+ estradiol
implant
women
605
(monkey), 347
progesterone
prematurely
during proliferative
phase, 177 normal cycle (monkey), normal menstruating
6 19
women, 329
response
to LH-RH, 605
response
to LH-RH in lactating
women with regular
menstrual
cycles resumed,
605
LH/hCG level, effect
of norethisterone
effect
of Nova-T,
LHRH (luteinizing
enanthate,
553
553
hormone
releasing
hormone)
LHRH analogue, D-Trp’-LH-RH,
619
D-trp’-pro’-NEt-LHRH, [N-AcD-Trp”’ LH-RH stimulation,
,D-p-Cl-Phe2,D-Phe’,D-Ala? effect
in lactating Lipids and side effects, Lipoprotein
195 of ethinyl
effect
menstrual
of medroxyprogesterone
619
to gonadotropin cycles resumed,
acetate
responses 605
in Nigerian
women, 161
pattern, of subdermal
effect
of TCu 200, 281
Lippes loop, effect
implant
capsules
on levels of hemoglobin,
in anemic Lippes loop D, effect Lithospermum
-LH-RH, + norgestrel
women with regular
effect
Lithosperm
estradiol
levonorgestrel,
281
serum iron and iron binding capacity
women, 3ll
on plasminogen
(Lithospermum ruderale
containing
ruderale
plant extract
activator
activity
in uterine
tissue, 131
plant extract) (lithosperm),
effect
on thyroidal
32P
uptake (chick), 639
662
JUNE 1983 VOL. 27 NO. 6
CONTRACEF’TION Luteal phase length, anovulatory effect
luteal cycle (monkey), 505
of agonistic
Luteinization
and antagonist
of unruptured
Luteinized
anovulatory
Mechanism
of action,
follicles,
follicle
estrogen-progestogen progestogen-only
anovulatory
of LH-RH (monkey), 619 luteal cycle (monkey), 505
(monkey), 505
combinations, formulations,
Medroxyprogesterone
analogues
acetate,
531
531
effect
in Nigerian
on blood lipids and side effects
women, 161 Menses induction,
polymeric
controlled
release
vaginal delivery
system
containing
(15S)15-methyl PGP 9 a methyl ester, 141 Menstrual
bleeding,
Menstrual
cycle,
effect
effect
of vaginal device releasing
during breast-feeding,
progesterone
563
prematurely
during proliferative
phase, 177 subcellular
distribution
myometrium,
of estradiol
and estrone
in endometrium
and
409
Menstrual
cycle of lactating
Menstrual
disturbances,
of ethinyl estradiol + norgestrel
women, effect
pituitary-ovarian levonorgestrel-releasing
function,
299
capsules,
473
on
Nova-T, 473 Menstrual
flow,
effect
of levonorgestrel-releasing
effect
of Nova-T, 473
Mestranol
473
+ norethindrone,
comparison effect Metabolic
capsules,
with ethinyl estradiol
+ norethiadrone
of daily vitamin supplementation
clearance
rate of estradiol,
effect
in clinical trials, 453
on side effects of testosterone
and discontinuation, + estradiol
465
implant (monkey),
347 Metabolic
clearance
rate of testosterone,
implant 15-Methyl-PGF3
effect
of testosterone
+ estradiol
(monkey), 347
c1methyl ester,
trimester, Mexican women, effects Missed oral contraceptive
preoperative
cervical
dilatation
in late first
51 of synthetic
steroid
contraceptives
on biliary lipid composition,
591
pills,
JUNE 1983 VOL. 27 NO. 6
663
CONTRACEPTION hormonal
consequences,
risk of pregnancy, Morning or evening
531
531
administration,
norethisterone, Morning urine samples
from normally
urinary Morphology Motility
initiation
Multiload
estrogens,
of luteinized
of spermatozoa,
subcellular
menstruating
women, determination
of total
329
anovulatory
Cu250, randomized
Myometrium,
of ethynyloestradiol +
pharmacokinetics
153
follicle effect
comparative
distribution
(monkey),
505
of gossypol
on epididymis
evaluation
of Cu-IUDs,
of estradiol
and estrone
(rat), 391 75
during menstrual
cycle,409 ,D-p-CI-Phe2,D-Phe6,D-Ala101
[N-Ac-D-T&’
ovulation Naproxen-sodium,
(monkey),
danazol
folicles
Nigerian
women,
contraception,
effect
and phenytoin, enanthate,
of anovulatory when used for
on blood lipids and
activity
interaction
contraception,
(rat), 401
563
(monkey) 423 in Mexican
women,
591
553
level,
after
administration
after
postabortal
effect
on clotting
on biliary lipid composition
postabortal
acetate
during breast-feeding,
Norethisterone
Norethisterone
and functions
39
interaction
acceptability
Norethisterone effect
on
161
and ethanol,
Norethisterone,
effect
505
of medroxyprogesterone
side effects, Norethindrone
(monkey),
with ethinyloestradiol + norgestrel
compared
postcoital
(A-LH-RH),
619
use in study of morphology
luteinized Nausea,
-LH-RH
of ethynyloestradiol + norethisterone, norethisterone
of phenytoin
(monkey),
enanthate,
153
553
423
Nova-T, contraception postabortal Nulliparous
after
pregnancy
contraception,
women,
incidence
clinical
trials,
termination,
473
553 of pelvic inflammatory
disease
during Cu-7
ill
Nursing women, influence
of copper T, 13
influence
of ethinyl
estradiol + levonorgestrel
on lactation
and infant
growth,
1,13, 27
JUNE 1983VOL. 27 NO. 6
CONTRACEPTION
Onset of post-treatment
period, danazol compared
when used for postcoital Operative
complications
with ethinyloestradiol
contraception,
at vacuum aspiration,
A 2 PGEl methyl ester,
+ norgestrel
39
pre-operative
16,16_dimethyl-trans-
339
Oral contraceptive, drug interactions, effectiveness
531
and interfering
factors,
ethinylestradiol + desogestrel ethinylestradiol
+ desogestrel
sequential,
ethinyl e&radio1 + 1-norgestrel,
1,13, 27
ethinylestradiol + levonorgestrel
triphasic,
+ norethindrone
ethinyl estradiol + norgestrel,
with ferrous
ethinyl oestradiol + levonorgestrel,
453, 465
439
ethynylestradiol + levonorgestrel,
439
311 with ferrous
ethynyloestradiol + norethisterone,
fumarate,
311
153
531
mestranol + norethindrone norethisterone,
fumarate,
triphasic,
ethynylestradiol + levonorgestrel of action,
577
299, 605
ethinyl oestradiol + levonorgestrel
mechanism
577 577
591
ethinyl estradiol + levonorgestrel, ethinyl estradiol
531
monophasic,
with ferrous
fumarate,
453, 465
563
Oral contraceptive
steroids,
Oral contraceptive
users, inadvertent
influence
on development pregnancies,
or growth of prolactinomas,
69
531
OrFan weight assay, RMI 12, 936 (rat), 95 Outcome
variables,
vacuum aspiration
with electric Ovarian cycle, plasminogen Ovarian effect,
with IPAS Modified Gynecologic
pump and standard activator
progesterone
released
activity
Syringe compared
hand pump, 63 during different
prematurely
phases, 131
during proliferative
phase, 177
Ovulation, anovulatory
luteal cycle (monkey), 505
effect
of agonistic
effect
of hCG antagonist
Oxytocin,
uterine
and antagonistic
response
Parous women, incidence Pelvic inflammatory
analogues
of LH-RH (monkey), 619
(rat), 515
(Fuinea pig), 239 of pelvic inflammatory
disease,
incidence
disease during 01-7 clinical trials, 111
in clinical trials with Cu-7,111
PG (prostaglandin) Pharmacokinetic
parameters
for ethynyloestradiol,
JUNE 1983 VOL. 27 NO. 6
after
morning or eveninF administration
665
CONTRACEPTION
of ethynyloestradiol Pharmacokinetic
parameters
+ norethisterone,
for norethisterone,
153 after morning or evening administration
of ethynyloestradiol + norethisterone, Pharmacokinetics
after
morning or evening administration,
+ norethisterone, cervical Phospholipids
PGE2 methyl sulfonylamide,
dilatation
and norethisterone, level, effect
in late first trimester, interaction
of injectable
Pill dosage and unusual pill regimens, Pituitary,
ovarian and endometrial function
preoperative
51
(monkey), 423 medroxyprogesterone
effectiveness
effects,
during proliferative Pituitary-ovarian
ethynyloestradiol
153
WPhenoxy-o-17,18,19,20-tetranor Phenytoin
153
acetate,
161
of oral contraceptive
progesterone
released
regimens,
531
prematurely
phase, 17’7
during menstrual
cycle of lactating
of ethinyl estradiol + norgestrel,
women, effect
299
Plasma renin activity, effect
of ethinylestradiol
+ desogestrel
monophasic,
effect
of ethinylestradiol
+ desogestrel
sequential,
effect
of ethinylestradiol + levonorgestrel
Plasminogen Platelet
activator,
changes in uterine
count, interaction
Postabortal
between
577 577
triphasic,
577
tissue induced by IUDs, 131
ethanol and contraceptive
steroids
(rat), 401
contraception,
norethisterone
enanthate,
553
Nova-T, 553 Postcoital
contraceptive,
danazol,
39
ethinyloestradiol + norgestrel, Postcoital
test, effect
of gossypol,
Potassium
concentration,
Predictive
value of serum ferritin insertion,
effect
39 571
of gossypol on epididymis in anemia development
(rat), 391 after T Cu 220
289
Pregnancy, effect
of synthetic
inadvertent Pregnancy
666
androstane
administration
derivatives
(baboon), 201
of oral contraceptives,
531
termination,
immediate
contraception
with levonorgestrel-releasing
immediate
contraception
with Nova-T, 473
capsules,
JUNE
473
1983 VOL. 27 NO. 6
CONTRACEPTION Preoperative
cervical
dilatation
prostaglandin Pre-operative
cervical
in late first trimester,
analogues
dilatation
dimethyl-trans-A2 Progestasert,
effect
and laminaria,
in termination
of different
51
of first trimester
PGEl methyl ester,
on levels of hemoglobin,
comparison
pregnancy,
16,16-
339
serum iron and iron binding capacity
in anemic women, 311 ProgestationaUantiprogestational Progesterone
activity,
effect
on RMI 12,936 (rat, rabbit),
95
level,
anovulatory
luteal cycle (monkey), 505
during menstrual
cycle of lactating
women, 299
effect
of A-LH-RH (monkey),
619
effect
of D-Trp’-LH-RH
(monkey), 619
effect
of ethinylestradiol
+ desogestrel
monophasic,
effect
of ethinylestradiol
+ desogestrel
sequential,
effect
of ethinylestradiol
+ levonorgestrel
effect
of ethinyl estradiol + norgestrel
577 577
triphasic,
577
during menstrual
cycle of lactating
women, 299 effect
of norethisterone
effect
of Nova-T, 553
enanthate,
effect
of synthetic
effect
of vaginal device releasing
androstane
553
derivatives
(baboon), 201
progesterone
prematurely
during proliferative
phase, 177 normal cycle (monkey), 619 Progesterone
released
prematurely
endometrial Prolactin
during proliferative
effects,
phase, pituitary,
ovarian and
177
level,
during menstrual
cycle, 299, 605
during menstrual
cycle of lactating
299, 605
women,
effect
of ethinylestradiol + desogestrel
monophasic,
effect
of ethinylestradiol + desogestrel
sequential,
effect
of ethinylestradiol
effect
of ethinyl estradiol + norgestrel,
effect
of ethinyl estradiol
+ levonorgestrel + norgestrel
triphasic,
577 577 577
605 during-menstrual
cycle of lactating
women, 299 effect
of ethinyl estradiol + norgestrel cycles resumed,
JUNE 1983 VOL. 27 NO. 6
in lactating
women with regular menstrual
605
667
CONTRACEPTION Prolactinomas, Proliferative
influence
of oral contraceptive
phase premature endometrial
Proposed
standard
Prostaglandin
exposure
effects,
steroids
on development
to progesterone,
pituitary,
or growth, 69
ovarian and
177
for laboratories
involved in development
of hCG vaccines,
627
analogue,
9-deoxo-l6,l6-dimethyl-9-methylene 16,16_dimethyl-trans
PGE2, 51
A2PGEl methyl ester,
15-methyl PGE2 a methyl ester,
51, 339
51
16-phenoxy- w-17,18,19,20-tetranor
PGE2 methyl sulfonylamide,
51
(15S)15-methyl PGFZc, methyl ester, 141 Prostaglandin
analogues,
comparison
first trimester Protein
pattern
Quatelet’s
Release
for preoperative
abortion,
of cauda fluid, effect
dilatation
of cervix in late
51 of gossypol on epididymis
(rat), 391
index,
effect
of ethinyl estradiol + 1-norgestrel,
effect
of norethisterone
enanthate,
rates of levonorgestrel,
591
591
capsules,
homogeneous
rods and covered
rods, 483
Removals, levonorgestrel-releasing
capsules,
473
Nova-T, 473 randomised Reproductive
comparative
evaluation
of Cu-IUDs, 75
organ weights,
effect
of cadmium
effect
of cadmium + zinc (rat), 521
Reproductive
tissues,
Risk of pregnancy,
(rat), 521
effect
of testosterone
+ estradiol
missed oral contraceptive
RMI 12,936 (176 -hydroyx-7o
implant (monkey), 363
pills, 531
-methyl-5-androstene-3-one)
(15S)15-methyl PGP2 Q free acid and methyl ester, extraction purification
and quantitation,
(15S)15-methyl PGP2 cI level in plasma, polymeric delivery system,
Saf-T-Coil,
effect
Second trimester
on plasminogen
release
controlled
release
and second trimester
activator
termination,
system containing
668
polymeric
for menses induction
pregnancy
controlled
vaginal
141
(15S)15-methyl PGF2 c( methyl ester, system
from plasma,
141
activity
polymeric
vaginal delivery
pregnancy
termination,
in uterine tissue, 131 controlled
(15S)15-methyl PGP20
release
vaginal delivery
methyl ester, 141
JUNE 1983 VOL. 27 NO. 6
141
CONTRACEPTION Semen characteristics,
effect
of testosterone
+ estradiol
implant (monkey), 383
Serum iron level, effect
of ethynylestradiol
+ levonorgestrel
in anemic women, 311
effect
of ethynylestradiol
+ levonorgestrel
with ferrous fumarate
in
anemic women, 311 effects
of IUDs in anemic women, 311
Sex hormone binding globulin, effect
of ethinylestradiol
effect
of ethinylestradiol + desogestrel
+ desogestrel
effect
of ethinylestradiol
monophasic, sequential,
+ levonorgestrel
577 57’7
triphasic,
577
Side effects, comparison
of different
cervical
prostaglandin
dilatation
analogues
in late first trimester
of ethinyl oestradiol + levonorgestrel
comparison
and laminaria abortion,
for preoperative
51
monophasic
and triphasic
versions,
439 of mestranol + norethindrone
comparison
danazol compared
with ethinyloestradiol
contraception, effect
of vitamin
injectable
and ethinyl estradiol + norethindrone, + norgestrel
453
when used for postcoital
39
supplementation
medroxyprogesterone
levonorgestrel-releasing
during oral contraceptive acetate,
capsules,
use, 465
161
473
Nova-T, 473 pre-operative
16,16-dimethyl-trans-A
Sodium concentration, Somatic
effect
tissue responses,
Sperm concentration,
effect
effect
2 PGEl methyl ester,
of gossypol on epididymis of testosterone
+ estradiol
of gossypol on epididymis
339
(rat), 391 implant (monkey), 363
(rat), 391
Sperm motility effect
of gossypol,
effect
of gossypol on epididymis
571 (rat), 391
Sperm population, effect
of cadmium (rat), 521
effect
of cadmium + zinc (rat), 521
Sperm production, Spinnbarkeit,
effect
of testosterone
normal menstruating
Stability
of solutions,
Steroids,
effect
assessment
on testosterone
JUNE 1983VOL.27N0.6
+ estradiol
implant (monkey), 347
women, 329 for D-trp’-pro’-NEt-LHRH, synthesis
195
in testis (dog), 431
669
CONTRACEPTION Subcellular
distribution,
estradiol
during menstrual Subdermal
in endometrium
and myometrium
implant,
capsules
containing
capsules
releasing
covered
rods containing
covered
rods releasing
homogeneous
levonorgestrel,
123
levonorgestrel,
rods releasing
on clinical
483
levonorgestrel,
483
levonorgestrel,
capsules,
polydimethylsiloxane
TCu 200, effect
123, 281
levonorgestrel,
levonorgestrel-releasing Subdermal
and estrone
cycle, 409
implant,
chemistry,
483
473 testosterone
+ estradiol
(monkey), 347, 363, 383
281
T Cu 220, effect
of serum ferritin
predictive
and other hematological
value of serum ferritin
parameters,
in anemia development
289
after insertion,
289
TCu-220C, effect
on levels of hemoglobin,
serum iron and iron binding capacity
in
anemic women, 311 randomized Termination
rates,
comparative
evaluation
random&d
comparative
on Cu-IUDs, 75 evaluation
of Cu-IUDs, 75
Terminations, of mestranol + norethindrone
comparison
norethindrone, effect Testis,
of vitamin
inhibition
Testis function, Testosterone
somatic Testosterone
during oral contraceptive
synthesis
of testosterone
by steroids
+ estradiol
use, 465
(dog), 431
implant (monkey), 347
+ estradiol,
contraceptive effect
453
supplementation
of testosterone effect
and ethinyl estradiol +
on testis
efficacy function
tissue responses blood production
(monkey), 383 (monkey), 347 (monkey), 363 rate, effect
of testosterone
+ estradiol
implant
(monkey), 347 Testosterone
670
level,
effect
of cadmium
effect
of cadmium + zinc (rat), 521
(rat), 521
effect
of ethinylestradiol
+ desogestrel
monophasic,
effect
of ethinylestradiol
+ desogestrel
seqential,
effect
of ethinylestradiol
+ levonorgestrel
triphasic,
577
577 577
JUNE 1983VOL. 27N0.6
CONTRACEPTION
effect
of subdermal
effect
of TCu 200, 281
effect
of testosterone
testicular Testosterone
implant
+ estradiol
production
metabolic
capsules
after
clearance
containing
levonorgestrel,
281
implant (monkey), 347
testosterone
+ estradiol
implant (monkey), 347
rate, effect
of testosterone
+ estradiol
implant
(monkey), 347 Testosterone
synthesis
Thyroid stimulating
inhibition
in testis (dog), 431
hormone level,
effect
of subdermal
effect
of TCu ZOO,281
implant capsules
containing
levonorgestrel,
281
Thyroid weight, effect
of lithosperm
(chick), 639
effect
of lithosperm
and propyithiouracil
Thyroidal
(chick), 639
32P uptake,
effect
of lithosperm
(chick), 639
effect
of lithosperm
and propylthioiuracil
effect
of lithosperm
and thyroid-stimulating
Thyroxine
hormone (chick), 639
level,
effect
of subdermal
effect
of TCu 200, 281
Time of use and corrosion, Total urinary estrogens, normally Toxicological Traditional
studies,
implant capsules
containing
levonorgestrel,
281
MLCu250 and MLCu375 IUDs, 85
determination menstruating zoapatle
in morning urine samples from women, 329
aqueous crude extract
remedy from Mexico, zoapatle,
Triglycerides
(rat, dog), 255
211
level,
effect
of injectable
medroxyprogesterone
effect
of subdermal
implant capsules
effect
of TCu 200,281
Triiodothyronine
acetate,
161
containing
levonorgestrel,
281
implant capsules containing
levonorgestrel,
281
level,
effect
of subdermal
effect
of TCu 200, 281
Triphasic
(chick), 639
ethinyl oestradiol + levonorgestrel, on acceptability,
Urine samples collected
comparison
to monophasic
in the morning from normally menstruating
determination
version
439 of total urinary estrogens,
JUNE 1983VOL. 27 NO. 6
women,
329
671
CONTRACEPTION Use-effectiveness, Uterine
of mestranol + norethindrone
comparison
norethindrone,
and ethinyl estradiol +
453
contractility, effect
of hexanic
extract
of zoapatle
aqueous crude extract
(rat,
guinea pig), 267 effect
of kauradienoic
effect
of zoapatle
Uterine
contractions,
Uterine
response,
acid (rat, guinea pig), 267
aqueous crude extract
increase
associated
dialysed
extract
oxytocin
(guinea pig), 239
Uterine
tissue,
of zoapatle
changes
crude extract
of plasminogen
potency,
Uterotonic
potency
of several
various lvlontanoa species,
Uterotonic
potency
of wild and cultivated
Uterotonic
properties,
Vacuum aspiration,
specimens
zoapatle
and standard
of zoapatle
(guinea pig), 239
(guinea pig), 239
of RMI 12,936 (rat), 95 Syringe compared
with electric
pump
hand pump, 63
of abortifacient,
containing
induced by IUDs, 131
(guinea pig), 239
specimens
effect
211
227
of zoapatle
IPAS Modified Gynecologic
Vaginal administration
activity
aqueous crude extract
activity,
of zoapatle,
(guinea pig), 239
activator
Uterotonic
Uterotrophic/estrogenic
(rat, guinea pig, dog), 267
with aaueous plant extract
polymeric
(lSS)lS-methyl
of -E. -f Coli to contraceptive
controlled
PGF2 u methyl ester,
release
delivery
system
141
Vaginal colonization relation
significantly Vaginal contraceptive, Vaginal device,
factors,
gossypol
releasing
effect
discontinuation,
Withdrawal
bleeding,
Zoapatle
a traditional
comparison
side effects
and
tomentosa remedy
+ norgestrel
when used for
39
of ethinyl oestradiol
versions,
aqueous plant extract
672
177
with ethinyloestradiol
on cadmium-induced
(Montanoa
acid gel, 57 1
on oral contraceptive
contraception,
and triphasic Zinc, effect
497
497
465
danazol compared postcoital
acetic
progesterone,
Vitamin supplementation, Vomiting,
methods,
associated
+ levonorgestrel
monophasic
439
sterility
(rat), 521
(Cerv.) s.s.p. tomentosa
(Funk.)),
from Mexico, ‘211 associated
biological
and uterotonic
biological
observations,
with increase
properties
in uterine
contractions,
of aqueous plant extract
211
(guinea pig), 239
211
JUNE 1983 VOL. 27 NO. 6
CONTRACEPTION botanical clinical effect
and ecological observations,
of hexanic
determinants,
227
211
extract
(kauradienoic
acid) upon uterine
contracility
(rat,
guinea pig, dog), 267 history,
211
isolation
of active principle(s),
toxicological Zoapatle
211
and clinical studies of aqueous crude extract
(rat, dog), 255
aoueous crude extract,
effect
on uterine
contractility
effect
on uterine
strips of different
JUNE 1983 VOL. 27 NO. 6
(rat, guinea pig, dog), 267 animal species,
239
673